Research programme: CAR-T cell therapies - National Cancer Center Japan/Optieum Biotechnologies
Latest Information Update: 02 Jan 2023
At a glance
- Originator National Cancer Center (Tokyo); Optieum Biotechnologies
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours